

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. (Currently Amended) Tetrapeptide lysyl-glutamyl-aspartyl-tryptophane ~~amid~~ amide of the general formula Lys-Glu-Asp-Trp-NH₂[SEQ ID NO:1].
2. (Canceled).
3. (Currently Amended) ~~Pharmaceutical substance~~ A pharmaceutical composition ~~comprising of peptide nature, capable of regulating glucose level; containing an active peptide agent and a pharmaceutically admissible carrier, which is distinguished by the fact that it contains as its active base and an effective quantity of tetrapeptide Lys-Glu-Asp-Trp-NH₂[SEQ ID NO:1].~~
4. (Currently Amended) ~~The substance described in pharmaceutical composition~~ of claim 3, wherein said substance is presented in a form which is suitable for oral administration.
5. (Currently Amended) ~~The substance described in pharmaceutical composition~~ of claim 3, wherein said substance is presented in a form which is suitable for parenteral administration.
6. (Currently Amended) ~~The~~ A method of prophylaxis and/or treatment of diabetes mellitus, which consists in administering to the patient ~~of the pharmacological substance, containing as an active peptide agent~~ an effective amount of tetrapeptide Lys-Glu-Asp-Trp-NH₂ [SEQ ID NO:1] ~~tetrapeptide in doses of 0,1-30 µg/kg of the body weight at least once a day for a period necessary for attaining a therapeutic effect.~~
7. (Currently Amended) The method of claim 6 wherein the ~~pharmacological substance is intended for parenteral administration~~ tetrapeptide is administered parenterally.
8. (Currently Amended) The method of claim 6 wherein the ~~pharmacological substance is intended for oral administration~~ tetrapeptide is administered orally.

9. (Currently Amended) The method of ~~claim 7~~ claim 6 wherein the ~~pharmacological substance described in claims 3-5 is active when~~ tetrapeptide is administered in doses of ~~0,1-30~~ 0.1-30 mg/kg of the body weight.